FDA Expands Approval of Dupixent(R) (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma

Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option Only biologic medicine approved for children with oral corticosteroid-dependent ... Biopharmaceuticals, FDA Regeneron Pharmaceuticals, Dupixent, dupilumab, asthma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news